Amicus Therapeutics sets IPO at 5 million shares

WASHINGTON (Reuters) - Biopharmaceutical firm Amicus Therapeutics Inc. on Thursday set its planned initial public offering at 5 million shares for an estimated $14 to $16 each.

Morgan Stanley, Merrill Lynch & Co., JPMorgan, Lazard Capital Markets, and Pacific Growth Equities LLC are underwriting the IPO, according to an amended filing with the U.S. Securities and Exchange Commission.

Amicus intends to list its stock on the Nasdaq under the symbol "FOLD." (FOLD.O)